What is jakavi used for?1,2

Jakavi is used to treat adult patients with an enlarged spleen or with symptoms related to myelofibrosis (MF), a rare form of blood cancer. MF is a disorder of the bone marrow, in which the marrow is replaced by scar tissue. The abnormal marrow can no longer produce enough normal blood cells and as a result the spleen becomes significantly enlarged. Symptoms of patients with MF include abdominal discomfort, fever, night sweats, bone pain and weight loss.

Jakavi is also used to treat patients with polycythaemia vera (PV) who are resistant to or intolerant of hydroxyurea. PV is a disorder of the bone marrow, in which the marrow produces too many red blood cells. The blood becomes thicker as a result of the increased red blood cells.

How jakavi works1,2
Jakavi contains ruxolitinib, which belongs to a group of medicines called protein kinase inhibitors. It is used to block the action of certain enzymes (called Janus Associated Kinases), which can help reduce the size of the spleen and relieve symptoms such as fever, night sweats, bone pain and weight loss. Jakavi can help reduce the risk of serious blood or vascular complications. In patients with PV, it can reduce the volume of red blood cells.

 

More information
For more information about jakavi please consult:

Summary of Product Characteristics (SmPC) for jakavi
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Patient Information Leaflet (PIL) for jakavi
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

 

Abbreviations

MF, myelofibrosis; PV, polycythaemia vera.

References

  1. Novartis Pharmaceuticals UK Ltd. Jakavi summary of product characteristics.
  2. Novartis Pharmaceuticals UK Ltd. Jakavi Patient Information Leaflet.

 

 

ONC20-C054 June 2020.
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.